Efficacy and Safety of Direct-Acting Antiviral Drugs in Hepatitis C Virus Infection Genotype-3 in South Punjab Pakistan
AbstractObjective: To find out the safety and efficacy of direct anti-viral agents for the treatment of cHCV genotype-3 infection.
MethodsThis retrospective study included record 1536 cHCV patient who were treated at medical outpatient department (MOPD) of Medical Unit-1 of Bahawal Victoria Hospital, Bahawalpur from April 2018 to April 2020. Polymerase chain reaction (PCR) was done 3 months after completion of treatment to note sustained virologic response (SVR). Patients were compared for various demographical characteristics, laboratory findings, comorbidities, types of direct anti-viral agents (DAAs) and treatment related adverse-effects.
Results In a total of 1536 patients, 725 (47.2%) were male and 811 (52.8%) female. Overall, mean age was noted to be 43.2+12.8 years. Overall, SVR was noted in 1447 (94.2%) patients while there was no statistically significant difference between SVR of different DAAs (p=0.0656). Significantly linked factors with No-SVR were found to be older age (46.2+12.3 vs. 43.8+10.4 years, p=0.0368), higher BMI (27.7+3.1 vs. 26.8+2.3, p=0.001), cirrhosis (49.4% vs. 8.4%, p<0.001) and non-responders/relapsers (23.6% vs. 11.5%, p=0.001). Generalized weakness was noted to be the most frequently reported on-treatment side-effect in 471 (30.7%) while body aches & pain and fever were the other most frequently reported side-effects in 230 (14.5%) and 145 (9.4%).
Conclusion Overall sustained virologic response with various kinds of direct-acting antiviral agents for chronic hepatitis C virus infection genotype-3 was noted to be good and comparable with real world data from different parts of the world. Increasing age, higher BMI, cirrhosis and non-responders/relapsers were found to have significant association with non-achievement of SVR. Adverse-effects related to different direct anti-viral agents were few and mild in nature.
Keywords:Direct acting anti-viral agents, genotype-3, hepatitis C, sustained virologic response
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments firstname.lastname@example.org